1.Review Educational Program for Diabetics in Nagano Matsushiro General Hospital: Diabetic Patients' Lifestyle Compared with the Results of the 2007 Health and Nutrition Survey in Nagano in Prefecture
Akiko IHARA ; Mayumi MIYAO ; Sawako YOKOTA ; Toshiaki SAKAI ; Shaw AKIZUKI
Journal of the Japanese Association of Rural Medicine 2012;60(6):758-763
The purpose of this study was to investigate the characteristics of the lifestyle of our diabetic patients under treatment in our hospital in order to provide them with a more effective education.
Method:A questionnaire survey was conducted on the diabetics to find their lifestyle. The results were compared with the data on the lifestyle of the general population (GP) in Nagano prefecture, obtained from the 2007 Health and Nutrition Survey in Nagano. The relationship between lifestyle of the diabetics and stages of change model was also examined.
Results and discussion:The ratio of those who did not have breakfast and ate between meals was larger in our diabetic subjects than the corresponding figure of the GP. Diabetic women in the stage of maintenance ate breakfast more regularly than diabetic women in the other stages. This suggested that it was necessity to recognize the stage of diabetics and to educate them according to the stage. More people in the diabetics were smokers than in the GP, and the frequency was higher in diabetic men in the stage of preparation and maintenance than in the other stages. Therefore, diabetics in the stage of preparation and higher should be advised to quit smoking, if they are smokers. The diabetics seemed to feel stressed less than the GP. Those diabetics who habitually slept less than six hours said that they were under stress. This indicated that there was a possibility of deterioration in blood sugar level, and that sleeping time was one of the important factors. The diabetics did not take less exercise than the GP, especially in diabetic men in the stage of preparation and diabetic women in the stage of pre-contemplation and contemplation. This showed that the diabetics without regular exercise should be aware of the necessity of therapeutic exercise, and require individual programs.
2.Clinical analysis of influenza A (H1N1) pdm09
Keiko Yano ; Mizuho Nagao ; Ryoji Ichimi ; Toshiaki Ihara ; Takashi Nakano
An Official Journal of the Japan Primary Care Association 2013;36(3):160-165
Introduction : To clarify clinical features of influenza A (H1N1) pdm09, we analyzed patients admitted during the early stage of the pandemic.
Methods : Analysis covered pediatric patients hospitalized with this virus during the first 3 months of the pandemic.
Results : The patients (average age, 7.7 years) were older than those in previous analyses and were divided by the reason for admission. The group with respiratory complaints (39 patients) accounted for 40%, in contrast to 10% observed previously, and had a significantly high prevalence of bronchial asthma history (21 patients). Nine patients with dyspnea symptoms preceding fever experienced a shorter period (1.6 days) from onset to admission. These patients had elevated WBC counts (13644/µL) and longer hospitalization (6.0 days). Twenty-nine patients had false negative results in the initial rapid influenza diagnostic tests (RIDTs). Many of them belonged to the respiratory complaints group (20 patients) and developed pneumonia (15 patients). These patients required treatment other than that with anti-viral agents, e.g., oxygen therapy (18 patients), leading to longer hospitalization (4.5 days).
Conclusion : During the first 3 months of the pandemic, many patients were admitted with respiratory complaints. They had a high prevalence of bronchial asthma history. Patients with dyspnea symptoms preceding fever and those who were initially RIDT-negative required advanced treatments, resulting in longer hospitalization.
3.Rotavirus vaccine and health-care utilization for rotavirus gastroenteritis in Tsu City, Japan
Kazutoyo Asada ; Hajime Kamiya ; Shigeru Suga ; Mizuho Nagao ; Ryoji Ichimi ; Takao Fujisawa ; Masakazu Umemoto ; Takaaki Tanaka ; Hiroaki Ito ; Shigeki Tanaka ; Masaru Ido ; Koki Taniguchi ; Toshiaki Ihara ; Takashi Nakano
Western Pacific Surveillance and Response 2016;7(4):21-36
Background: Rotavirus vaccines were introduced in Japan in November 2011. We evaluated the subsequent reduction of the health-care burden of rotavirus gastroenteritis.
Methods: We conducted active surveillance for rotavirus gastroenteritis among children under 5 years old before and after the vaccine introduction. We surveyed hospitalization rates for rotavirus gastroenteritis in children in Tsu City, Mie Prefecture, Japan, from 2007 to 2015 and surveyed the number of outpatient visits at a Tsu City clinic from 2010 to 2015. Stool samples were obtained for rotavirus testing and genotype investigation. We assessed rotavirus vaccine coverage for infants living in Tsu City.
Results: In the pre-vaccine years (2007-2011), hospitalization rates for rotavirus gastroenteritis in children under 5 years old were 5.5, 4.3, 3.1 and 3.9 cases per 1000 person-years, respectively. In the post-vaccine years (2011-2015), the rates were 3.0, 3.5, 0.8 and 0.6 cases per 1000 person-years, respectively. The hospitalization rate decreased significantly in the 2013-2014 and 2014-2015 seasons compared to the average of the seasons before vaccine introduction (p < 0.0001). In one pre-vaccine year (2010-2011), the number of outpatient visits due to the rotavirus infection was 66. In the post-vaccine years (2011-2015), the numbers for each season was 23, 23, 7 and 5, respectively. The most dominant rotavirus genotype shifted from G3P[8] to G1P[8] and to G2P[4]. The coverage of one dose of rotavirus vaccine in Tsu City was 56.5% in 2014.
Conclusion: After the vaccine introduction, the hospitalization rates and outpatient visits for rotavirus gastroenteritis greatly decreased.
4.Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Kazuhiko NAKAMURA ; Eikichi IHARA ; Hirotada AKIHO ; Kazuya AKAHOSHI ; Naohiko HARADA ; Toshiaki OCHIAI ; Norimoto NAKAMURA ; Haruei OGINO ; Tsutomu IWASA ; Akira ASO ; Yoichiro IBOSHI ; Ryoichi TAKAYANAGI
Gut and Liver 2016;10(6):917-924
BACKGROUND/AIMS: The ability of endoscopic submucosal dissection (ESD) to resect large early gastric cancers (EGCs) results in the need to treat large artificial gastric ulcers. This study assessed whether the combination therapy of rebamipide plus a proton pump inhibitor (PPI) offered benefits over PPI monotherapy. METHODS: In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66). The Scar stage (S stage) ratio after treatment was compared, and factors independently associated with ulcer healing were identified by using multivariate analyses. RESULTS: The S stage rates at 4 and 8 weeks were similar in the two groups, even in the subgroups of patients with large amounts of tissue resected and regardless of CYP2C19 genotype. Independent factors for ulcer healing were circumferential location of the tumor and resected tissue size; the type of treatment did not affect ulcer healing. CONCLUSIONS: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).
Adenoma
;
Cicatrix
;
Cytochrome P-450 CYP2C19
;
Endoscopy
;
Genotype
;
Humans
;
Multivariate Analysis
;
Prospective Studies
;
Proton Pump Inhibitors
;
Proton Pumps*
;
Protons*
;
Rabeprazole
;
Stomach Neoplasms
;
Stomach Ulcer*
;
Ulcer
5.Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Kazuhiko NAKAMURA ; Eikichi IHARA ; Hirotada AKIHO ; Kazuya AKAHOSHI ; Naohiko HARADA ; Toshiaki OCHIAI ; Norimoto NAKAMURA ; Haruei OGINO ; Tsutomu IWASA ; Akira ASO ; Yoichiro IBOSHI ; Ryoichi TAKAYANAGI
Gut and Liver 2016;10(6):917-924
BACKGROUND/AIMS: The ability of endoscopic submucosal dissection (ESD) to resect large early gastric cancers (EGCs) results in the need to treat large artificial gastric ulcers. This study assessed whether the combination therapy of rebamipide plus a proton pump inhibitor (PPI) offered benefits over PPI monotherapy. METHODS: In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66). The Scar stage (S stage) ratio after treatment was compared, and factors independently associated with ulcer healing were identified by using multivariate analyses. RESULTS: The S stage rates at 4 and 8 weeks were similar in the two groups, even in the subgroups of patients with large amounts of tissue resected and regardless of CYP2C19 genotype. Independent factors for ulcer healing were circumferential location of the tumor and resected tissue size; the type of treatment did not affect ulcer healing. CONCLUSIONS: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).
Adenoma
;
Cicatrix
;
Cytochrome P-450 CYP2C19
;
Endoscopy
;
Genotype
;
Humans
;
Multivariate Analysis
;
Prospective Studies
;
Proton Pump Inhibitors
;
Proton Pumps*
;
Protons*
;
Rabeprazole
;
Stomach Neoplasms
;
Stomach Ulcer*
;
Ulcer
6.Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy.
Kazuhiko NAKAMURA ; Kazuya AKAHOSHI ; Toshiaki OCHIAI ; Keishi KOMORI ; Kazuhiro HARAGUCHI ; Munehiro TANAKA ; Norimoto NAKAMURA ; Yoshimasa TANAKA ; Kana KAKIGAO ; Haruei OGINO ; Eikichi IHARA ; Hirotada AKIHO ; Yasuaki MOTOMURA ; Teppei KABEMURA ; Naohiko HARADA ; Yoshiharu CHIJIIWA ; Tetsuhide ITO ; Ryoichi TAKAYANAGI
Gut and Liver 2012;6(4):423-426
BACKGROUND/AIMS: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. METHODS: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. RESULTS: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24+/-2.41 g/dL) than in the C group (9.44+/-2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. CONCLUSIONS: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.
Anti-Inflammatory Agents, Non-Steroidal
;
Endoscopy
;
Endoscopy, Digestive System
;
Hemoglobins
;
Hemorrhage
;
Hemostasis, Endoscopic
;
Humans
;
Incidence
;
Medical Records
;
Peptic Ulcer